EDMUS activities
Help in patient care
In increasing numbers of neurology departments in France and elsewhere the EDMUS software is used as an aid in daily medical practice, for patient monitoring during the various visits and hospitalizations. By providing an instant overview of the disease and its treatments, it helps in the decisions that are needed to adjust the monitoring and treatment of the patient. It also helps identify, among all patient files in the department, those that fit a given profile. It is then easy to determine which patients could take part in a given study or drug trial.
In all regional health networks devoted to Multiple Sclerosis (MS) in France, the EDMUS software is the tool of choice used to handle patient data. These networks aim at improving patient care by strengthening the expertise and harmonizing the practices in the region concerned, as well as promoting synergy between hospital and primary care physicians. They are financed by funds from the Agences Régionales d’Hospitalisation (ARH) and Unions Régionales des Caisses d’Assurance Maladie (URCAM).
The EDMUS network and software can be very helpful in monitoring the effect of drugs marketed as multiple sclerosis treatments in the context of post-marketing pharmaco-epidemiological studies. A first example of such studies is the TYSEDMUS study, started on 20 November 2007, entitled "Evaluation of the utilisation patterns, tolerance, security and efficacy of natalizumab (Tysabri®) in the treatment of relapsing-remitting multiple sclerosis in the French EDMUS network". The promoter is the French Medicines Agency (AFSSAPS).